Benzinga | Jul 29, 2021 10:52AM EDT

RBC Capital Maintains Sector Perform on Biomarin Pharmaceutical, Raises Price Target to $88

RBC Capital analyst Kennen MacKay maintains Biomarin Pharmaceutical (NASDAQ:BMRN) with a Sector Perform and raises the price target from $87 to $88.